Key result
Antidepressant therapy, particularly with SSRIs and SNRIs, may increase the risk of developing Takotsubo cardiomyopathy in patients with affective and anxiety disorders due to elevated catecholamine levels.
Why the study?
The mechanisms underlying susceptibility to the development and recurrence of Takotsubo cardiomyopathy are not completely understood, particularly regarding the role of psychiatric disorders and psychotropic medications.
Does psychotropic medication therapy affect the development of Takotsubo cardiomyopathy in adults with psychiatric disorders?
Design
Review
Authors
Loading...
Antidepressants warrant caution for possible TTC precipitation in psychiatric patients; challenges safety assumptions and leaves open need for RCTs.
Systematic Review
Does psychotropic medication therapy affect the development of Takotsubo cardiomyopathy in adults with psychiatric disorders?
Antidepressants may pose a risk for precipitating Takotsubo cardiomyopathy in patients with psychiatric disorders, warranting baseline ECG screening and close cardiovascular monitoring.
Valeriy Zvonarev (2019) conducted a systematic review in Takotsubo Cardiomyopathy. Psychotropic medications (SSRIs, SNRIs, TCAs) vs. No psychotropic medication use / healthy controls was evaluated. Antidepressant therapy, particularly with SSRIs and SNRIs, may increase the risk of developing Takotsubo cardiomyopathy in patients with affective and anxiety disorders due to elevated catecholamine levels.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: